NCT04514796View on ClinicalTrials.gov

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions

Healthy

Interventions

DRUG

Adalimumab

SB5 (adalimumab), 40 mg, single-dose

Trial Locations (1)

14050

Parexel International GmbH, Early Phase Clinical Unit Berlin, Berlin

All Listed Sponsors

lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT04514796 - Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter